SCHEMBL6824196

SCHEMBL6824196

NCCCCNc1nc(Cl)nc2c1ncn2C1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.56
ADORA3 P0DMS8 3/20 0.55
ADORA1 P30542 3/20 0.55
FLT3 P36888 9/20 0.55
PDGFRA P16234 6/20 0.55
CDK2 P24941 5/20 0.55
CDK1 P06493 3/20 0.47
ADORA2A P29274 1/20 0.47
CCNB2 O95067 1/20 0.46
CCNE2 O96020 1/20 0.46
CDK4 P11802 1/20 0.46
CCNB1 P14635 1/20 0.46
CCND1 P24385 1/20 0.46
CCNE1 P24864 1/20 0.46
CCNB3 Q8WWL7 1/20 0.46
YTHDC1 Q96MU7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6821513 0.99 CTSL (0.58) CTSLADORA3ADORA1FLT3PDGFRA
SCHEMBL5193703 0.92 ADORA3 (0.53) CTSLADORA3ADORA1FLT3PDGFRA
SCHEMBL6817879 0.89 CTSL (0.70) CTSLADORA3ADORA1FLT3CDK1
SCHEMBL6820572 0.88 CTSL (0.72) CTSLADORA3ADORA1FLT3PDGFRA
SCHEMBL6817663 0.88 CTSL (0.72) CTSLADORA3ADORA1FLT3PDGFRA
SCHEMBL8204168 0.88 CTSL (0.72) CTSLADORA3ADORA1FLT3PDGFRA
SCHEMBL6817790 0.88 CTSL (0.58) CTSLADORA3ADORA1FLT3PDGFRA
SCHEMBL8110131 0.88 CTSL (0.72) CTSLADORA3ADORA1FLT3PDGFRA
SCHEMBL6947217 0.88 CTSL (0.72) CTSLADORA3ADORA1FLT3PDGFRA
SCHEMBL6820593 0.87 CTSL (0.66) CTSLADORA3ADORA1FLT3CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056745-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2004-06-16 EP disclosed
US-6413974-B1 INHIBITORS OF CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; PREVENTING APOPTOSIS IN NEURONAL CELLS; ANTINEOPLASTIC AGENTS; NEURONAL INJURY AND DEGENERATION; CEREBROVASCULAR DISEASE AVENTIS PHARMACEUTICALS INC. 2002-07-02 US disclosed